Is a Treatment For Your Cancer Sitting on a Dusty Shelf?
December 15, 2014 · Comments Off
THE AH-HA THAT HOW A THING HAS BEEN USED DOESN’T LIMIT HOW IT COULD BE...
NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
September 30, 2014 · Comments Off
The New England Journal of Medicine reports positive results of a phase 1 clinical trial of the drug crizotinib against the subset of lung cancer marked by rearrangement of the gene ROS1.
University of Colorado’s Online Screening for Rare Lung Cancer Subtypes Opens Door to New Kind of Clinical Trial
August 21, 2014 · Comments Off
CU Cancer Center clinical trial tests the drug ponatinib against lung cancer with mutation in the gene FGFR1. Online questionnaire and free lung cancer tissue testing at CU determines eligibility.
A physician’s trip through the disease looking glass
June 2, 2014 · Comments Off
Let me tell you about the very rich. They are different from you and me,”...
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
AURORA, Colo -The Journal of Clinical Oncology reports the case of a woman diagnosed with...
CU docs work to boost minorities in (and leading) cancer trials
April 17, 2014 · Comments Off
Focus on training minority investigators By Todd Neff Clinical trials of cancer therapies are most...
“Weeding the garden” with radiation allows ALK+ lung cancer patients to continue crizotinib, increasing survival
January 28, 2014 · Comments Off
CU Cancer Center study shows that patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease. Eliminating these pockets of resistant disease allows patients to continue treating the overall condition with crizotinib, leading to improved 2-year survival rate compared with patients forced to discontinue the drug sooner.
Layers of Support
December 2, 2013 · Comments Off
Palliative care consult service helps families tailor care to meet personal desires. Barb Cassou was...
Bitter melon juice prevents pancreatic cancer in mouse models
December 2, 2013
New Program Connects Patients and Survivors at CU Cancer Center
January 26, 2015 · No comments
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer clinical trials cancer grants cancer prevention cancer research colorado Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith